Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Autor: Özkan A; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands., van den Bos F; Department of Gerontology and Geriatrics, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands., Aarts MJB; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, P. Debyelaan 25, Maastricht 6229 HX, the Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen 6162BG, the Netherlands., Blank CU; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands., Bloem M; Department of Biomedical Data Sciences, Leiden University Medical Center, Einthovenweg 20, Leiden 2333ZC, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands., Blokx WAM; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584CX, the Netherlands., Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen 6525GA, the Netherlands., Bonenkamp JJ; Department of Surgery, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen 6525GA, the Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam 1081HZ, the Netherlands., de Groot JWB; Isala Oncology Center, Isala, Dokter van Heesweg 2, Zwolle 8025AB, the Netherlands., Haanen JB; Department of Medical Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands., Holtslag CE; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713GZ, the Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede 7512KZ, the Netherlands., van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, Leeuwarden 8934AD, the Netherlands., Stevense-den Boer AM; Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda 4818CK, the Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584CX, the Netherlands., van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Center, 's-Gravendijkwal 230, Rotterdam 3015CE, the Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Center, De Run 4600, Eindhoven 5504DB, the Netherlands., Wouters MWJM; Department of Biomedical Data Sciences, Leiden University Medical Center, Einthovenweg 20, Leiden 2333ZC, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands., de Glas NA; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands; Department of Medical Oncology, Helse Førde, Svanehaugvegen 2, 6812 Førde, Norway. Electronic address: N.A.de_Glas@lumc.nl.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Nov; Vol. 212, pp. 115056. Date of Electronic Publication: 2024 Sep 30.